Rhinovirus News and Research

RSS

Rhinovira are the most common viral infective agents in humans, and a causative agent of the common cold (about 49.12159% of the cases of the common cold are caused by this virus). It is lytic in nature. There are over a 100 recognized types of rhinovira that differ based on their varying surface proteins.

Cloth masks should be machine washed daily during COVID-19, study says

A team of researchers reports that cloth masks effectively protect against infection if they are washed every day. The researchers recommend daily washing of cloth masks at high temperatures to reduce the likelihood of contamination and transmission of viruses such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease (COVID-19).

11 Oct 2020

SARS-CoV-2 infection analysis could help fight against COVID-19

Researchers in the United States has provided a detailed catalog of the interactions that occur between host cell proteins and RNA and the RNA of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the course of infection.

7 Oct 2020

Newly developed fusion protein could improve COVID-19 research

Researchers at the Paul Scherrer Institute in Switzerland have developed a high-quality recombinant virus protein that could be applied in the development of vaccines against the 2019 novel coronavirus (2019-nCoV) and in the detection of novel viruses or antibodies.

30 Sep 2020

SARS-CoV-2 emergence linked with decrease in circulation of common respiratory viruses

Analysis of samples taken to test for respiratory viruses over the past five years suggests that the emergence of SARS-CoV-2 was associated with a large drop in circulation of other common respiratory viruses during the first wave.

26 Sep 2020

Linoleic acid binds SARS-CoV-2 spike protein

Now, a team of researchers at the Max Planck-Bristol Center for Minimal Biology and Bristol's School of Biochemistry has identified a druggable pocket in the virus's spike protein that can be used to prevent the infection of cells. The study findings, published in the journal Science, are a groundbreaking discovery that will help develop new therapies and drugs to stem the growing pandemic.

24 Sep 2020

Study invalidates Ebselen and other broad-spectrum SARS-CoV-2 Mpro inhibitors

Other novel compounds with Mpro inhibitory activity have also been claimed to have antiviral activity. These include ebselen, disulfiram, tideglusib, carmofur, shikonin, and PX-12. A new research paper discusses the role of these molecules as potential Mpro inhibitors in the prevention of SARS-CoV-2 infection.

18 Sep 2020

Using SARS-CoV-2 epitope to construct a vaccine

A new study published on the preprint server bioRxiv* in August 2020 reports the use of prediction and advanced simulation techniques to identify a novel T cell epitope on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could serve as the basis for a customized vaccine with broad-based efficacy.

30 Aug 2020

Fewer rhinovirus infections in Philadelphia after COVID-19 stay-at-home orders

Philadelphia and its surrounding counties issued a series of "stay-at-home" orders on March 17, 2020 in an effort to curb the spread of COVID-19.

20 Aug 2020

Study shows how picornaviruses infect the host cell

Picornaviruses is a family of viruses that can cause a number of different diseases, including polio, meningitis, and in rare cases myocarditis, encephalitis, and paralysis.

13 Aug 2020

Novel short ACE2 isoform may influence SARS-CoV-2 susceptibility

A study led by researchers at the University of Southampton, UK, has identified a novel short isoform of the full-length receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses to gain entry to host cells.

3 Aug 2020

As winter comes other viruses will compete with SARS-CoV-2 for susceptible hosts

A new study published on the preprint server medRxiv in July 2020 traces how COVID-19 became the predominant cause of respiratory infection in the period from early January until the present.

10 Jul 2020

New assay rapidly tests SARS-CoV-2 neutralization and screens antivirals

Researchers at the University of Texas Medical Branch, Galveston, have developed a new platform that can rapidly test neutralizing antibody activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and perform high-throughput screening of potential antiviral agents.

24 Jun 2020

Impact Biomedical's COVID-19 research published in peer-reviewed scientific journal

SGX-listed Singapore eDevelopment Limited's wholly owned subsidiary Impact Biomedical Inc. announced today that their COVID-19 research with Global Research and Discovery Group Sciences, conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc., was published in the peer-reviewed scientific journal Molecules on June 11, 2020.

18 Jun 2020

Inhaled steroids reduce ACE2 expression in COPD lungs

A new study by scientists at Imperial College London, University of Newcastle and Prokarium, and published on the preprint server bioRxiv* in June 2020 examines the role played by inhaled corticosteroids (ICS) in the risk of acquisition of COVID-19 infection by COPD patients.

15 Jun 2020

Prediction of incubation period for COVID-19 and other viruses

A new study published on the preprint server bioRxiv* in May 2020 provides a method to estimate the incubation period for any new pathogen, which could help to define the optimal quarantine period necessary to keep the spread of the causative agent in check.

22 May 2020

Wearing surgical masks in public may help limit the spread of COVID-19

Surgical masks may help prevent infected people from making others sick with seasonal viruses, including coronaviruses, according to new research that could help settle a fierce debate spanning clinical and cultural norms.

5 Apr 2020

UNC researchers look to NGS for better understanding of COVID-19

It might be the future of diagnostic testing for common infections, and could prove to be a crucial tool for understanding and fighting novel viruses.

23 Mar 2020

Modified form of poliovirus shows potential as cancer vaccine in animal studies

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for pediatric brain tumors when used as part of a cancer vaccine.

31 Jan 2020

Stopping cold viruses dead by blocking replication

The common cold virus (and its more deadly cousins, the viruses that cause polio and acute flaccid myelitis) may just have met its nemesis. In a recent study published in the journal Nature Microbiology on September 16, 2019, scientists reported a potentially successful new approach to stop cold viruses from replicating inside human cells – by blocking the formation of a protein that is vital to this process.

17 Sep 2019

Stanford-UCSF researchers report new cure for common cold in human cells and mice

Temporarily disabling a single protein inside our cells might be able to protect us from the common cold and other viral diseases, according to a study led by researchers at Stanford University and University of California-San Francisco.

16 Sep 2019